JPRN-UMIN000038492已完成未知
Safety trial of oral coadministration of 5-aminolevulinic acid phosphate and Salacia extract - Safety trial of oral coadministration of 5-aminolevulinic acid phosphate and Salacia extract
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Taking medicines for chronic disease 2) Taking functional food that may affect the trial 3) Participation in any clinical trial within 90 days of the commencement of the trial 4) In pregnancy or nursing a child 5) Judged as ineligible by clinical investigators
研究者
相似试验
已完成
不适用
Safety trial of oral coadministration of 5-aminolevulinic acid phosphate with sodium ferrous citrate to healthy subjectsHealthy volunteersJPRN-UMIN000022825Hiroshima University22
进行中（未招募）
不适用
A pilot study into the effect of 5-Aminolevulinic Acid Photodynamic Therapy in the management of oral Lichen Planus - Pilot study into the use of PDT for Oral Lichen PlanusOral Lichen PlanusEUCTR2006-004696-35-GBGreater Glasgow and Clyde Health Board60
进行中（未招募）
1 期
5-Aminolevulinic acid (5-ALA) in children and adolescents with differnt types of brain tumoursintra-axial brain tumor (malignant glioma, astrocytoma, malignant ependymoma, AT/RT, Oligodendroglioma, etc.)MedDRA version: 20.0Level: LLTClassification code 10006154Term: Brain tumor NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005669-54-DEniversität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Personal und Recht80
尚未招募
2 期
Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with supratentorial brain tumorsbrain tumorsSupratentorial10029211NL-OMON52327Westfälische Wilhelms-Universität Münster10
进行中（未招募）
1 期
5-Aminolevulinic acid (5-ALA) in children and adolescents with different types of brain tumoursEUCTR2014-005669-54-NLWestfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel80